Sepracor Submits NDA For Xopenex HFA; Metered Dose Inhaler Could Triple Target Population
This article was originally published in The Pink Sheet Daily
Executive Summary
Metered dose bronchodilator market is more than twice the size of nebulizer market, firm says. Sepracor believes sales force’s co-detailing of Xopenex and the pending sleep agent Estorra creates strong primary care synergy.